News und Analysen

Ultragenyx Pharmaceutical (NASDAQ:RARE), a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street

MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from

UnitedHealth Group (NYSE: UNH) stock investors will want to digest this information before making the important decision to invest in or divest from this stock.

*Stock prices used were the

Geron (NASDAQ:GERN), a biotechnology company focused on therapies for blood disorders, released its second quarter 2025 results on August 6, 2025. The headline news was a sharp acceleration in

Evolus (NASDAQ:EOLS), a performance beauty company specializing in aesthetic neurotoxins and hyaluronic acid (HA) dermal fillers, reported Q2 2025 results on August 5, 2025. The headline news is a

Norwegian Cruise Line Holdings (NYSE: NCLH) benefited from a significant bump following earnings, rising 9% in the following trading session. With record revenue and strength in all three of its

I can actually think of multiple reasons to buy shares of Pfizer (NYSE: PFE) stock, but if I had to focus on only one, I'd choose its dividend. The stock's dividend yield was recently a whopping

Personalis (NASDAQ:PSNL), a precision genomics company focused on ultra-sensitive minimal residual disease (MRD) detection and comprehensive tumor profiling for cancer, reported its second-quarter

Vertex Pharmaceuticals (NASDAQ: VRTX) reported its second-quarter results after the market closed on Monday. Its shares plunged more than 17% in early trading on Tuesday.

Were Vertex's Q2 results

Advanced Micro Devices (NASDAQ:AMD), a leading semiconductor company best known for its processors and graphics cards, released its results on August 5, 2025. The quarter’s headline news was a

LeMaitre Vascular (NASDAQ:LMAT), a medical device company focused on vascular surgeons, reported its latest quarterly earnings after the bell on August 5, 2025. The company delivered GAAP results

QuidelOrtho (NASDAQ:QDEL), a global provider of diagnostic testing solutions, released its financial results for the quarter ended June 29, 2025, on August 5, 2025. The most notable headline was a

Esperion Therapeutics (NASDAQ:ESPR), a specialty pharmaceutical company focused on cardiovascular disease, delivered higher-than-expected GAAP results in its latest earnings release. On August 5

ImmunityBio (NASDAQ:IBRX), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating

Halozyme Therapeutics (NASDAQ:HALO), a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter’s headline is

Ocular Therapeutix (NASDAQ:OCUL), a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant

Amgen (NASDAQ:AMGN), a leading biotechnology company with a wide portfolio of innovative medicines, released its second-quarter 2025 results on August 5, 2025. The headline news was a double-digit

Advanced Energy Industries (NASDAQ:AEIS), a global leader in precision power conversion solutions for the semiconductor, data center, industrial, and medical sectors, released its Q2 2025 earnings

Curis (NASDAQ:CRIS), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss

Nvidia (NASDAQ: NVDA) declined 0.97% on Tuesday to close at $178.26, retreating modestly from recent highs as semiconductor stocks faced pressure amid fresh trade policy concerns. Trading volume

Shares of the large pharmaceutical company Pfizer (NYSE: PFE) closed up over 5% today after a strong earnings report that included raising its full-year profit outlook for 2025.

In the second

Image source: The Motley Fool.

Need a quote from a Motley Fool analyst? Email [email protected]

Columbia Banking System(NASDAQ:COLB) delivered operating results for fiscal Q2 2025 reflecting a 14%

Vericel (NASDAQ:VCEL), a cell therapy specialist focused on sports medicine and burn care, reported its Q2 2025 results on July 31, 2025. The most headline-worthy news was the 20% year-over-year

It's been a little over a month since I first warned investors about the danger of investing in a new space stock, space station builder Voyager Technologies (NYSE: VOYG). After a smashingly